IPO of SOPHiA GENETICS SA with a listing on Nasdaq
On July 22, 2021, SOPHiA GENETICS SA, priced its USD 234 million IPO, consisting of an offering of 13,000,000 ordinary shares at a price of USD 18.00 per share. The ordinary shares have been approved for listing on the Nasdaq Global Select Market under the symbols “SOPH”, and trading began on July 23, 2021. The offering closed on July 27, 2021.
J.P. Morgan, Morgan Stanley, Cowen and Credit Suisse acted as joint book-running manager for the initial public offering.
Headquarted in Saint-Sulpice, Switzerland, SOPHiA GENETICS is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research.
Lenz & Staehelin acted as Swiss counsel to the underwriters. The team included Patrick Schleiffer, Stephan Erni, Patrick Schärli and Patrick Sattler (all Corporate and Capital Markets).